{"name":"TUMOR","title":"","children":[{"id":"breast","name":"breast","presenterLast":"breast","children":[{"id":10616,"name":"breast_10616","title":"Synergy of an anti-HER2 ADC TAK-522 (XMT-1522) in combination with anti-PD1 monoclonal antibody (mAb) in a syngeneic breast cancer model expressing human HER2","presenterFirst":"Tary","presenterLast":"Traore","keywords":"HER-2;Cancer immunotherapy;Checkpoint;XMT-1522","target":"HER2","tumor":"breast","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":10689,"name":"breast_10689","title":"HER2-targeted antibody drug conjugates induce host immunity and target cancer stem cells and the efficacy can be enhanced by anti-PD-L1","presenterFirst":"Qiao","presenterLast":"Li","keywords":"Cancer stem cell;antibody drug conjugate;anti-PD-L1;TILs","target":"HER2","tumor":"breast","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"colorectal","name":"colorectal","presenterLast":"colorectal","children":[{"id":10703,"name":"colorectal_10703","title":"MEDI7247: A first in class antibody drug conjugate targeting ASCT2 in a range of solid tumors","presenterFirst":"Kevin","presenterLast":"Schifferli","keywords":"Targeted drug delivery;Antibody;Solid tumors;Pyrrolobenzodiazepines","target":"ASCT2","tumor":"colorectal","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"lung","name":"lung","presenterLast":"lung","children":[{"id":10703,"name":"lung_10703","title":"MEDI7247: A first in class antibody drug conjugate targeting ASCT2 in a range of solid tumors","presenterFirst":"Kevin","presenterLast":"Schifferli","keywords":"Targeted drug delivery;Antibody;Solid tumors;Pyrrolobenzodiazepines","target":"ASCT2","tumor":"lung","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"lymphoma","name":"lymphoma","presenterLast":"lymphoma","children":[{"id":3562,"name":"lymphoma_3562","title":"Anti-tubulin antibody drug conjugates potentiate venetoclax activity in non-Hodgkin lymphoma by targeting MCL-1","presenterFirst":"Dhara","presenterLast":"Amin","keywords":"Bcl-2 protein family;venetoclax;Lymphoma: non-Hodgkin's lymphoma;antibody drug conjugates","target":"CD79b","tumor":"lymphoma","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"multiple","name":"multiple","presenterLast":"multiple","children":[{"id":10662,"name":"multiple_10662","title":"Discovery and development of MEDI7247, a novel Pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2, for treating hematological and solid cancers","presenterFirst":"Nabendu","presenterLast":"Pore","keywords":"Pyrrolobenzodiazepines;Antibody;Solid tumors;Multiple myeloma","target":"ASCT2","tumor":"multiple","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":6760,"name":"multiple_6760","title":"Combination of the miniature drug conjugate PEN-866 with PARP inhibitors as a rational approach to overcoming limitations of PARP inhibitor monotherapy","presenterFirst":"Samantha","presenterLast":"Perino","keywords":"PARP;Combination studies;topoisomerase I inhibitor","target":"HSP90","tumor":"multiple","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"myeloma","name":"myeloma","presenterLast":"myeloma","children":[{"id":886,"name":"myeloma_886","title":"Additional mechanisms of action of SGN-CD48A in multiple myeloma and improved antitumor activity in combination with daratumumab","presenterFirst":"Timothy","presenterLast":"Lewis","keywords":"Antibody;Drug delivery;Microtubule-interfering agents;Multiple myeloma","target":"CD48","tumor":"myeloma","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"renal","name":"renal","presenterLast":"renal","children":[{"id":3971,"name":"renal_3971","title":"Head-to-head comparison of ADC and SMDC products, alone and in combination with antibody-IL2 fusion proteins","presenterFirst":"Samuele","presenterLast":"Cazzamalli","keywords":"Combination studies;Tumor Targeting;Targeted Cytotoxics;Immunocytokines","target":"CAIX","tumor":"renal","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]}]}
